Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03767595
Other study ID # PAS001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 19, 2019
Est. completion date September 1, 2030

Study information

Verified date May 2023
Source Uromedica
Contact Patrick Gora
Phone 7636949880
Email pgora@uromedica-inc.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.


Recruitment information / eligibility

Status Recruiting
Enrollment 145
Est. completion date September 1, 2030
Est. primary completion date September 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 50 Years and older
Eligibility Inclusion Criteria: 1. Subject is a male of at least 50 years of age. 2. Subject demonstrates stress urinary incontinence. 3. Subject has undergone a radical prostatectomy, transurethral resection of the prostate, or other prostate surgery. 4. Subject is willing and able to undergo surgical implantation of ProACT devices. 5. Subject is willing and able to comply with study-required follow-up activities, including annual telephonic follow -up interviews, for a period of 5 years from their date of initial implantation. This includes compliance even after possible explant of ProACT devices and/or possible implantation of subsequent therapies. 6. Subject is willing and able to sign the approved informed consent. 7. Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests). 8. Subject has a negative urine culture. 9. Subject has no known urogenital malignancy, other than previously treated prostate cancer. 10. Subject meets ONE of the following criteria: 1. Baseline Prostate-Specific Antigen (PSA) of less than or equal to 2.5ng/mL; 2. Baseline PSA > 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater than or equal to 25% of total PSA; 11. Physician determines subject to be a suitable surgical candidate. Exclusion Criteria: 1. Subject has an existing urethral stricture, a history of any urethral strictures, or has ever had a urethrotomy. 2. Subject has undergone prostate surgery or any anti-incontinence surgery within the last 12 months. 3. Subject has an artificial urinary sphincter or any components of a previously implanted artificial urinary sphincter in vivo. 4. Subject has undergone radiation therapy in the prostatic area within the last 12 months. 5. Subject has untreated or unsuccessfully treated detrusor instability or over-activity. 6. Subject has an atonic bladder. 7. Subject had, presently has, or is suspected of having bladder cancer. 8. Subject has untreated or unsuccessfully treated bladder stones. 9. Subject has detrusor sphincter dyssynergia. 10. Subject has known hemophilia or a bleeding disorder. 11. Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or respiratory arrest). 12. Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as indicated by an A1c test result of = 6.5%.

Study Design


Intervention

Device:
ProACT Adjustable Continence Therapy for Men
The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a port. During a minimally invasive outpatient procedure, the balloons are surgically placed in the area where the prostate was removed or resected.

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan
United States Emory University Atlanta Georgia
United States University of Colorado Denver Colorado
United States University of Florida Gainesville Florida

Sponsors (1)

Lead Sponsor Collaborator
Uromedica

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Effect of ProACT on Subsequent Stress Urinary Incontinence(SUI) Therapy This data will be collected with a "Post ProACT Explant Subsequent Therapy Questionnaire".
This questionnaire will ask 3 questions regarding the ProACT therapy
Did the ProACT therapy have a detrimental effect on the difficulty of the subsequent implant surgery?
Did the ProACT therapy significantly increase the time required to implant the subsequent implant surgery?
Did the ProACT therapy increase the surgical complication rate during the subsequent implant surgery?
The scale for each question is 0-1. 0 Meaning no effect (a "No" response on the questionnaire) and 1 being some effect ("Yes" response on the questionnaire). No effect (0) on subsequent SUI therapies is the better outcome.
5 years
Primary Urethral Strictures Cumulative incidence of ProACT-related clinically relevant urethral strictures over 5 years of follow up. 5 years
Primary Device Erosions Cumulative incidence of ProACT device erosions over 5 years of follow-up. 5 years
Primary Incontinence Quality of Life Questionnaire (I-QoL) Results on Validated Incontinence Quality of Life Questionnaire 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT04829357 - Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
Completed NCT05493735 - Lidocaine for Pessary Check Pain Reduction Phase 3
Completed NCT04512053 - A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence Phase 2
Active, not recruiting NCT06224335 - Measurement of Intravaginal and Intra-abdominal Pressure and Pad Test During Sports Activities (SPORTVAGPRES)
Recruiting NCT05304312 - The Role of Kegel Exercises Book to Improve Treatment in Stress Urinary Incontinence Women N/A
Not yet recruiting NCT05527665 - Sexual Fonction and Discomfort in Women After Midurethral Sling Surgery, Using PPSSQ
Not yet recruiting NCT04558762 - Ten Years Follow-up After Insertion of a MUS (Mid Urethral Sling) Due to Stress Urinary Incontinence
Withdrawn NCT02524366 - A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement N/A
Completed NCT01924728 - Efficacy of Magnetic Stimulation for Stress Urinary Incontinence N/A
Completed NCT01676662 - Solace European Confirmatory Trial N/A
Unknown status NCT01455779 - Lyrette: Renewing Continence Objective and Subjective Efficacy Study N/A
Terminated NCT01029106 - Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI) N/A
Withdrawn NCT00573703 - Laparoscopic Burch Colposuspension Versus Transobturatory Tape for the Treatment of Female Urinary Stress Incontinence Phase 4
Completed NCT01770691 - Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence N/A
Completed NCT01123096 - Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence? N/A
Completed NCT00234754 - Trans-Obturator Tape Versus Trans-Vaginal Tape for Stress Urinary Incontinence in Women N/A
Completed NCT00441454 - Retropubic vs. Transobturator Tension-free Vaginal Tape N/A
Completed NCT03985345 - Prospective Evaluation of the Connected EMY Biofeedback Probe in the Management of Stress Urinary Incontinence. N/A
Active, not recruiting NCT03671694 - Laser Vaginal Treatment for SUI N/A
Completed NCT04097288 - Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects Phase 1